Recce Pharmaceuticals — Phase III Indonesian DFI trial underway
Recce has reached a key milestone with the start of patient dosing in its Phase III Indonesian-focused study of the topical gel formulation (R327G)...
209 Views
Recce Pharmaceuticals — Funding secured to start Phase III pivotal trials
Recce is raising up to A$15.8m in equity fundraising through a now-completed A$5.0m share placement and an entitlement offer for remaining...
258 Views
Recce Pharmaceuticals — Gearing up for an eventful year for R327G
Recce is preparing to start a registrational Indonesian Phase III study of the topical gel formulation (R327G) of its lead anti-infective...
538 Views
Recce Pharmaceuticals — Positive R327G Phase II ABSSSI study results
Recce has reported positive results from its open-label Phase II study assessing RECCE® 327 topical gel (R327G) in patients with acute bacterial...
154 Views
Recce Pharmaceuticals - BPOM clearance to start Phase III R327G study
Recce received approval from the Indonesian Drug and Food Regulatory Authority, Badan POM (BPOM), to start its registrational Phase III study in...
319 Views